- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Developmental Disability.
Displaying page 1 of 2.
EudraCT Number: 2016-002875-81 | Sponsor Protocol Number: NL58621.041.16 | Start Date*: 2016-10-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Bumetanide for the Autism Spectrum Clinical Effectiveness Trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002821-32 | Sponsor Protocol Number: FENDEEP | Start Date*: 2021-12-09 | |||||||||||
Sponsor Name:Neurologia Aplicada, SLP | |||||||||||||
Full Title: The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes. | |||||||||||||
Medical condition: Five different types of developmental and epileptic encephalopathies (DEEs): SYNGAP1 and STXBP1 encephalopathies, inv-dup(15) encephalopathy, multifocal or bilateral Malformations of Cortical Devel... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000389-12 | Sponsor Protocol Number: 3.0 | Start Date*: 2013-09-11 |
Sponsor Name:Cardiff University | ||
Full Title: ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial | ||
Medical condition: Aggression and challenging behaviour in adults with learning disabilities | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004532-30 | Sponsor Protocol Number: MRZ60201_3091_1 | Start Date*: 2014-12-09 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of... | |||||||||||||
Medical condition: Chronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019519-39 | Sponsor Protocol Number: RAPIT | Start Date*: 2012-03-14 |
Sponsor Name:Erasmus MC - Department of Neurology | ||
Full Title: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial) | ||
Medical condition: Tuberous Sclerosis Complex | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000241-32 | Sponsor Protocol Number: NL80290.018.22 | Start Date*: 2022-08-08 | |||||||||||
Sponsor Name:Amsterdam UMC | |||||||||||||
Full Title: Effectiveness of L-serine dietary supplementation in children with a GRIN2B loss-of-function mutation: n-of-1 series | |||||||||||||
Medical condition: GRIN2B deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006444-21 | Sponsor Protocol Number: EC07/90076 | Start Date*: 2009-02-13 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Gregorio Marañón | |||||||||||||
Full Title: EFFECT OF 8-WEEK FATTY ACIDS OMEGA-3 TREATMENT ON OXIDATIVE METABOLISM IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMISED DOUBLE-BLIND CROSSOVER PLACEBO-CONTROLLED TRIAL. | |||||||||||||
Medical condition: autism spectrum disorders Trastornos del Espectro Autista | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002548-26 | Sponsor Protocol Number: 0139 | Start Date*: 2020-12-16 | ||||||||||||||||
Sponsor Name:Royal College of Surgeons in Irlenad | ||||||||||||||||||
Full Title: Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomised, placebo controlled trial | ||||||||||||||||||
Medical condition: Late onset sepsis & necrotising enterocolitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004729-97 | Sponsor Protocol Number: 2018-PWL | Start Date*: 2019-08-16 | |||||||||||
Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
Full Title: Randomized, controlled growth hormone study in children and adolescents with a Prader-Willi-like phenotype, followed by a two year open-label growth hormone study - effects on body composition, gro... | |||||||||||||
Medical condition: Prader-Willi-like phenotype | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002550-82 | Sponsor Protocol Number: NL76160.018.21 | Start Date*: 2022-12-22 | |||||||||||
Sponsor Name:Amsterdam UMC | |||||||||||||
Full Title: Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series | |||||||||||||
Medical condition: Gaucher disease type 3 | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003009-23 | Sponsor Protocol Number: ION582-CS1 | Start Date*: 2022-09-08 | |||||||||||
Sponsor Name:IONIS PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients with Angelman Syndrome | |||||||||||||
Medical condition: Angelman syndrome is a neurogenetic disorder caused by a loss of function of the maternally inherited UBE3A gene (chromosome 15) which codes for UBE3A ubiquitin protein ligase. AS presents early in... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002702-30 | Sponsor Protocol Number: ALXN1101-MCD-202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Origin Biosciences, Inc. | |||||||||||||
Full Title: A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A | |||||||||||||
Medical condition: Molydenum CoFactor Deficiency (MoCD) Type A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Prematurely Ended) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002481-40 | Sponsor Protocol Number: TAK-935-3002 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subj... | |||||||||||||
Medical condition: Lennox-Gastaut Syndrome (LGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA IT (Ongoing) FR (Ongoing) ES (Ongoing) LV (Ongoing) GR (Completed) NL (Completed) BE (Completed) PL (Ongoing) HU (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002480-22 | Sponsor Protocol Number: TAK-935-3001 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adul... | |||||||||||||
Medical condition: Dravet Syndrome (DS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA IT (Ongoing) FR (Ongoing) ES (Ongoing) LV (Ongoing) GR (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) HU (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005336-23 | Sponsor Protocol Number: Baby-OSCAR | Start Date*: 2014-12-16 |
Sponsor Name:University of Oxford | ||
Full Title: Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Pre-term Babies | ||
Medical condition: Patent ductus arteriosus of the newborn | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003124-16 | Sponsor Protocol Number: KH176-204 | Start Date*: 2021-01-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. | ||
Medical condition: Genetically confirmed mitochondrial disease | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023988-17 | Sponsor Protocol Number: 260777 | Start Date*: 2014-04-04 | |||||||||||
Sponsor Name:BrepCo Biopharma Limited | |||||||||||||
Full Title: Management of Hypotension In the Preterm: A multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age newborn | |||||||||||||
Medical condition: Low Blood Pressure | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002484-25 | Sponsor Protocol Number: TAK-935-2002(OV935) | Start Date*: 2019-04-29 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ... | ||
Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PT (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004216-22 | Sponsor Protocol Number: C602 | Start Date*: 2019-09-25 | |||||||||||
Sponsor Name:Soleno Therapeutics UK Ltd. | |||||||||||||
Full Title: An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome | |||||||||||||
Medical condition: Hyperphagia associated with Prader-Willi Syndrome (PWS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002080-26 | Sponsor Protocol Number: V58P15 | Start Date*: 2013-08-28 | |||||||||||
Sponsor Name:Novartis Vaccines & Diagnostics AG | |||||||||||||
Full Title: A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (tivc) or in Embryonated Eggs (TI... | |||||||||||||
Medical condition: volunteers at high risk for influenza-related complications (protection against influenza) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.